Clinical Trial Detail

NCT ID NCT04395079
Title Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center
Indications

female reproductive organ cancer

endometrial cancer

ovarian cancer

cervical cancer

Therapies

Tremelimumab

Durvalumab

Age Groups: adult senior

No variant requirements are available.